Related Experiment Video
Updated: Jan 3, 2026
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
A self-assembled RNA-triple helix hydrogel drug delivery system targeting triple-negative breast cancer
Lairong Ding1, Junwei Li, Changrong Wu
1Center of Cooperative Innovation for Chemical Imaging Functional Probes in Universities of Shandong, College of Chemistry, Shandong Normal University, Jinan 250014, P. R. China.
Abstract:
The major drawbacks of traditional RNA cancer therapies include low cellular uptake in vitro or in vivo, instability of in vivo circulation, nonspecific bio-distribution, and lack of targeting ability, which result in poor silencing efficiency. Herein, we developed a novel RNA-triple-helix hydrogel for the treatment of triple negative breast cancers (TNBCs) by incorporating RNA-triple-helix and siRNA duplexes of CXCR4 into the same RNA nanoparticles with no synthetic polycationic reagents added. The RNA-triple-helix consists of one tumour suppressor miRNA (miRNA-205) and one oncomiR inhibitor (miRNA-221), both of which showed an outstanding effect in synergistically abrogating tumours. The siRNA duplexes of CXCR4 were embedded into the RNA hydrogel to block breast cancer metastasis and conjugation of the LXL-DNA aptamer (apt-DNA-Chol) is an effective target DNA sequence for MDA-MB-231 cells. The self-assembly of the RNA-triple-helix hydrogel exhibited high selectivity of in vitro and in vivo absorption and controlling miRNA expression when compared to free miRNA and RNA transcripts. The well-developed gene delivery system provided a potential treatment with high specificity and selectivity toward TNBCs. This strategy can be implemented in triplex-helix hydrogel design to form novel miRNA combinations to treat various human cancers.
Insights
We developed a novel RNA-triple-helix hydrogel for treating triple-negative breast cancer (TNBC). This innovative hydrogel enhances RNA delivery, improving treatment specificity and efficacy against TNBC tumors.
Area of Science:
- Biotechnology
- Nanomedicine
- Oncology
Background:
- Traditional RNA cancer therapies suffer from poor cellular uptake, instability, and lack of targeting, leading to low silencing efficiency.
- Triple-negative breast cancer (TNBC) presents significant therapeutic challenges due to its aggressive nature and limited treatment options.
Purpose of the Study:
- To develop a novel RNA-triple-helix hydrogel for targeted TNBC treatment.
- To overcome the limitations of traditional RNA delivery systems for enhanced cancer therapy.
Main Methods:
- Incorporation of RNA-triple-helix (miRNA-205 and miRNA-221) and CXCR4 siRNA duplexes into RNA nanoparticles without synthetic polycationic reagents.
- Self-assembly of RNA nanoparticles into a hydrogel structure for improved delivery.
- Conjugation with LXL-DNA aptamer (apt-DNA-Chol) for targeting MDA-MB-231 cells.
Main Results:
- The RNA-triple-helix hydrogel demonstrated high selectivity for in vitro and in vivo absorption.
- Effective control over miRNA expression was observed compared to free miRNA and RNA transcripts.
- The system showed potential for blocking breast cancer metastasis by targeting CXCR4.
Conclusions:
- The developed RNA-triple-helix hydrogel offers a promising, highly specific, and selective gene delivery system for TNBC treatment.
- This strategy enables novel miRNA combinations in triplex-helix hydrogels for diverse human cancer therapies.
